Emmanuel Antonarakis
@EAntonarakis
Professor of Medicine, University of Minnesota, Prostate cancer physician-scientist
Congratulations @aliarafaa on developing the first prognostic blood-based PROTEOMIC biomarker for 177Lu-PSMA-617 efficacy, presented at ASCO ‘25. @UMNCancer @UMNews meetings.asco.org/abstracts-pres…
Congrats @aliarafaa for developing a new method for robust plasma exosome proteomics capable of detecting and quantifying >5000 proteins incl. PSMA, B7H3, TROP2 and STEAP1. A new blood-based biomarker is born! @UMNews mdpi.com/2072-6694/16/2…
Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert
Just in👉Two @TheLancetOncol papers on patient-reported QOL results in ph3 TALAPRO-2 trial👉in all-comer & HRR deficient mCRPC #ProstateCancer pts👉Improved OS without compromising QOL👇Links: bit.ly/3DWHlSR & bit.ly/3E3SSQi @urotoday @OncoAlert @PCFnews 👇
Largest retrospective study (N=93) of checkpoint-inhibitor efficacy in pts with dMMR mCRPC. Those with 3-4 modes of dMMR detection (protein IHC loss, gene alteration, MSI-hi, and TMB >20) have greatest survival. euoncology.europeanurology.com/action/showPdf…
A novel west-African germline founder mutation in HOXB13 (p.X285Kext) increases risk of high-grade prostate cancer but also enhances sensitivity to hormonal therapy. Congrats to PCF-funded Mayuko Kanayama 👏 @neerajaiims @PCFnews @urotoday @EdEsplin nature.com/articles/s4139…
Congrats @chadihcmd for this impactful study. You are a superstar ⭐️
Just in @CCR_AACR 👉Congrats @chadihcmd @umangtalking & @Huntsman_GU team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 @flatironhealth @FoundationATCG @RyonGraf 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i @OncoAlert @urotoday
Just in @CCR_AACR 👉Congrats @chadihcmd @umangtalking & @Huntsman_GU team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 @flatironhealth @FoundationATCG @RyonGraf 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i @OncoAlert @urotoday
Congratulations to Cathy Marshall on her two papers (in the same week!) exploring CH in solid tumors. This is an important and emerging field. @CathyHandy @TempusAI academic.oup.com/oncolo/article… mdpi-res.com/d_attachment/c…
Largest study of BRCA-associated cancers (24,309) shows that somatic tumor landscape is influenced by germline HRR muts: gBRCA1-altered cancers are enriched in somatic TP53 muts; gATM-altered cancers are depleted in TP53 mut. Congrats @aliarafaa @umncancer aacrjournals.org/clincancerres/…
Congrats to John Lozada (MD/PhD student) for deeply characterizing DLL3 expression in neuroendocrine cancers across 29 tumor sites. @carisls @UMNCancer @UMNews @mishabeltran aacrjournals.org/cancerrescommu…
Thank you @neerajaiims for conducting such a masterful interview and for recognizing the importance of this work
🧬 Groundbreaking insights into #FOXA1 in #ProstateCancer! Drs. @neerajaiims @huntsmancancer, @EAntonarakis and Justin Hwang, PhD @UMNCancer discuss: 🔹 FOXA1 mutations found in 15% of cases, higher in Asian (25%) & Black (20%) patients 🔹 Opposing clinical outcomes from…
Congratulations @CathyHandy and thanks to @mrinalpatnaik for mentoring us
Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies... sciencedirect.com/science/articl… @CathyHandy @EAntonarakis #Lutetium #Actinium #CH #PPM1D #TP53 @MayoCancerCare @JohnsHopkins @UMNews
The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Different FOXA1 classes have different biologic behaviors, clinical outcomes & racial clustering, esp. Class 1B and 2. @UMNcancer @scottdehm aacrjournals.org/clincancerres/…
Fascinating case report by @laurasenamd on a PCa patient with heterogeneous prostatic lesions, one with MMR deficiency and the other with BRCA2 loss, both of which led to metastatic outgrowths at different time points and selection pressures.
Amphicrine prostate cancer may be a transitional state between prostate adenoCa and small cell/NEPC. Upregulation of FOXA1 and OTX2 may play a role. Congrats to Megan Ludwig for this deep multi-omic analysis. @UMNCancer @umn_dom @DrJustinDrake @aliarafaa nature.com/articles/s4169…
Six genes involved in androgen production/ uptake/ conversion (APUC) distinguish ligand-driven PCa from AR-driven PCa, and have unique clinical outcomes. Congrats to Justin Hwang and his team. @NimaSharifiMD @charlesryanmd @carisls insight.jci.org/articles/view/…
Huge congrats to @CathyHandy and @BenTeply for this paradigm-breaking study. In BCR prostate cancer, Olaparib shows profound activity (w/out ADT!) in HRRm+ pts, esp. in BRCA2+ pts (100% response rate). @ThePCCTC @hopkinskimmel @umncancer jamanetwork.com/journals/jamao…
BRCAaway: Most compelling study suggesting that combined Abi+Olap is better than sequential Abi→Olap or Olap→Abi for BRCA/ATM-altered 1st-line mCRPC. Congrats to Maha Hussain, @ThePCCTC, @neerajaiims, @ArulChinnaiyan, @ZacheryReicher1, @LeonidasPlatan1 doi.org/10.1158/1078-0…
Congrats @eamontoye13 and @arafflemd on your 2 recent papers studying BRAF alterations in PCa. Unlike other BRAF-altered cancers, PCa is characterized by Class II muts and activating fusions, including AR-regulated BRAF fusions. aacrjournals.org/clincancerres/… oncotarget.com/article/28612/…
TRIUMPH study: First trial to show that PARP inhibition can work in the absence of ADT (hormone-sparing approach) for men with germline HRR-altered mHSPC, esp. for gBRCA2! Congrats to @MarkowskiGUOnc for leading this paradigm-shifting trial. @CathyHandy academic.oup.com/oncolo/advance…
